FindTrial
Sign In

Tumor Cells evaluation of expressing growth factor as a Potential Prognostic Marker in Ewingâ??s Sarcoma. Marker in Ewingâ??s Sarcoma.

â??Evaluation Of VEGF Expression Of Tumor Cells As a Potential Prognostic Marker In Ewingâ??s Sarcomaâ??. - VEGF

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/12/030114
Enrollment
150
Registered
2020-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C402- Malignant neoplasm of long bones of lower limb

Interventions

None listed

Sponsors

Roche Products India Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Histological proven, Ewingâ??s sarcoma patients, who were 1.Non-metastatic 2.All ages 3.Both osseous and non osseous 4.Treatment naïve 5.Treated uniformly on EFT 2001 protocol and underwent surgery as local treatment at TMH between 2010-2012 and with a minimum follow up of 6 months

Exclusion criteria

Exclusion criteria: 1. Prior treatment (chemotherapy, radiotherapy or surgery) 2. Metastatic disease at presentation 3. Pathologically inadequate specimens 4. Radiotherapy as definitive local treatment

Design outcomes

Primary

MeasureTime frame
Correlation of Tumour cells VEGF expression with overall survival (OS)Timepoint: From 2013-2018 with a minimum follow up of 6 months. Analysis Dec 2019—

Secondary

MeasureTime frame
Tumour cells VEGF expression correlation with histological necrosis (in resection specimens).Timepoint: from 2013-2018 with a minimum follow up of 6 months. Analysis (Dec 2019)—

Countries

India

Contacts

Public ContactMr Yogesh Kembhavi

Tata Memorial Hospital

dr_jyotibajpai@yahoo.co.in02224177287

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026